Cure My Disease

Don't miss your cure!

 Log in / Sign up

AI assistant aims to ease thyroid cancer anxiety before surgery

NCT ID NCT07690839

Symptom relief Sponsor: Cedars-Sinai Medical Center Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jul 08, 2026 · Last updated Sep 02, 2026 · Updated 3 times

Summary

This study tests whether an online educational tool called THRIVE, powered by artificial intelligence, can help people newly diagnosed with thyroid cancer feel less anxious and more confident about their treatment choices. Participants use the tool on their own device before meeting with their surgeon. The goal is to see if this approach reduces thyroid-cancer-related anxiety and improves shared decision-making.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
THRIVE AI educational agent
What this could lead to
If effective, this approach could reduce anxiety and help patients make more informed treatment decisions before surgery.
What could go wrong
This is a small pilot study (60 people) testing feasibility, so results may not be generalizable. The AI tool may not significantly reduce anxiety or improve decision quality.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 60 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Aug 2027

An estimate. Start dates often move.

Expected to finish

Sep 2028

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Newly diagnosed with either: 1. ≤2cm Bethesda 6 thyroid nodule (papillary thyroid carcinoma) (T1N0) 2. ≤2cm Bethesda 5 thyroid nodule 3. ≤2cm Bethesda 3-4 thyroid nodule with molecular testing that confers \>75% risk of malignancy * Able to understand and complete questionnaires independently in English * Access to an internet-enabled device for online surveys and intervention access Exclusion Criteria: * Cognitive impairment or other condition that, in the opinion of the investigators, would interfere with protocol participation * Has nodule \>2cm in size, or with non-papillary thyroid carcinoma histology * High-grade or poorly differentiated papillary thyroid carcinoma (PTC) variants * Central or lateral neck lymphadenopathy suspicious for PTC * Unfavorable nodule location, to be determined by the surgeon (e.g. Near dorsal surface (by recurrent laryngeal nerve); adjacent to trachea (risk of cartilage invasion) * Recurrent thyroid cancer case

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Papillary thyroid carcinoma are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

thyroid cancer thyroid gland papillary carcinoma Thyroid Neoplasms

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Thyroid cancer

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  2. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

More trials for these conditions

Other studies related to the condition(s) this trial covers.